Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS, Callaway CW, et al. Heart disease and stroke statistics – 2021 update: a report from the American Heart Association. Circulation. 2021;143(8):e254–743. https://doi.org/10.1161/CIR.0000000000000950.
Bozkurt B, Coats AJS, Tsutsui H, Abdelhamid CM, Adamopoulos S, Albert N, et al. Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Society and Writing Committee of the Universal Definition of Heart Failure: endorsed by the Canadian Heart Failure Society, Heart Failure Association of India, Cardiac Society of Australia and New Zealand, and Chinese Heart Failure Association. Eur J Heart Fail. 2021;23(3):352–80. https://doi.org/10.1002/ejhf.2115.
Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, et al. Temporal trends and patterns in heart failure incidence: a population-based study of 4 million individuals. Lancet. 2018;391(10120):572–80. https://doi.org/10.1016/S0140-6736(17)32520-5.
Article PubMed PubMed Central Google Scholar
Almeida AG, Carpenter JP, Cameli M, Donal E, Dweck MR, Flachskampf FA, et al. Multimodality imaging of myocardial viability: an expert consensus document from the European Association of Cardiovascular Imaging (EACVI). Eur Heart J Cardiovasc Imaging. 2021;22(8):e97–e125. https://doi.org/10.1093/ehjci/jeab053.
Di Carli MF, Maddahi J, Rokhsar S, Schelbert HR, Bianco-Batlles D, Brunken RC, Fromm B. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: implications for the role of myocardial viability assessment in management decisions. J Thorac Cardiovasc Surg. 1998;116(6):997–1004. https://doi.org/10.1016/S0022-5223(98)70052-2.
Beanlands RS, Ruddy TD, deKemp RA, et al. Positron emission tomography and recovery following revascularization (PARR-1): the importance of scar and the development of a prediction rule for the degree of recovery of left ventricular function. J Am Coll Cardiol. 2002;40(10):1735–43. https://doi.org/10.1016/s0735-1097(02)02489-0.
Di Carli MF, Asgarzadie F, Schelbert HR, et al. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy. Circulation. 1995;92(12):3436–44. https://doi.org/10.1161/01.cir.92.12.3436.
Ling LF, Marwick TH, Flores DR, et al. Identification of therapeutic benefit from revascularization in patients with left ventricular systolic dysfunction: inducible ischemia versus hibernating myocardium. Circ Cardiovasc Imaging. 2013;6(3):363–72. https://doi.org/10.1161/CIRCIMAGING.112.000138.
Panza JA, Ellis AM, Al-Khalidi HR, Holly TA, Berman DS, Oh JK, et al. Myocardial viability and long-term outcomes in ischemic cardiomyopathy. N Engl J Med. 2019;381:739–48. https://doi.org/10.1056/NEJMoa1807365.
Article PubMed PubMed Central Google Scholar
Perera D, Clayton T, O’Kane PD, Greenwood JP, Weerackody R, REVIVED-BCIS2 Investigators, et al. Percutaneous revascularization for ischemic left ventricular dysfunction. N Engl J Med. 2022;387(15):1351–60. https://doi.org/10.1056/NEJMoa2206606.
Babes EE, Tit DM, Bungau AF, Bustea C, Rus M, Bungau SG, et al. Myocardial viability testing in the management of ischemic heart failure. Life (Basel). 2022;12(11):1760. https://doi.org/10.3390/life12111760.
Article CAS PubMed PubMed Central Google Scholar
Beanlands RS, Hendry PJ, Masters RG, deKemp RA, Woodend K, Ruddy TD. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imaging. Circulation. 1998;98(19 Suppl):II51–6.
Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of thallium-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nuclear Med. 1994;35(4):707–15.
Schinkel AFL, Bax JJ, Poldermans D, Elhendy A, Ferrari R, Rahimtoola SH. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol. 2007;32(7):375–410. https://doi.org/10.1016/j.cpcardiol.2007.04.001.
Bax JJ, Poldermans D, Elhendy A, Boersma E, Rahimtoola SH. Sensitivity, specificity, and predictive accuracies of various noninvasive techniques for detecting hibernating myocardium. Curr Probl Cardiol. 2001;26(2):147–86. https://doi.org/10.1067/mcd.2001.109973.
Article CAS PubMed Google Scholar
Murthy VL, Naya M, Foster CR, Hainer J, Gaber M, Di Carli G, et al. Improved cardiac risk assessment with noninvasive measures of coronary flow reserve. Circulation. 2011;124(20):2215–24. https://doi.org/10.1161/CIRCULATIONAHA.111.050427.
Article PubMed PubMed Central Google Scholar
Bateman TM, Heller GV, McGhie AI, Friedman JD, Case JA, Bryngelson JR, et al. Diagnostic accuracy of rest/stress ECG-gated Rb-82 myocardial perfusion PET: comparison with ECG-gated Tc-99m sestamibi SPECT. J Nucl Cardiol. 2006;13(1):24–33. https://doi.org/10.1016/j.nuclcard.2005.12.004.
Kloner RA. Stunned and hibernating myocardium: where are we nearly 4 decades later? J Am Hear Assoc. 2020;9(3):e015502. https://doi.org/10.1161/JAHA.119.015502.
Madsen S, Dias AH, Lauritsen KM, Bouchelouche K, Tolbod LP, Gormsen LC. Myocardial viability testing by positron emission tomography: basic concepts, mini-review of the literature and experience from a tertiary PET center. Semin Nucl Med. 2020;50(3):248–59. https://doi.org/10.1053/j.semnuclmed.2020.02.010.
Chen K, Miller EJ, Sadeghi MM. PET based imaging of ischemic heart disease. PET Clin. 2019;14(2):211–21. https://doi.org/10.1016/j.cpet.2018.12.003.
Article PubMed PubMed Central Google Scholar
Grönman M, Tarkia M, Stark C, Vähäsilta T, Kibiniemi T, Lubberink M, et al. Assessment of myocardial viability with [15O]water PET: a validation study in experimental myocardial infarction. J Nucl Cardiol. 2021;28(4):1271–80. https://doi.org/10.1007/s12350-019-01818-5.
Cleland JGF, Calvert M, Freemantle N, Arrow Y, Ball SG, Bonser RS, et al. The heart failure revascularisation trial (HEART). Eur J Heart Fail. 2011;13(2):227–33. https://doi.org/10.1093/eurjhf/hfq230.
Wolff G, Dimitroulis D, Andreotti F, Kołodziejczak M, Jung C, Scicchitano P, et al. Survival benefits of invasive versus conservative strategies in heart failure in patients with reduced ejection fraction and coronary artery disease: a meta-analysis. Circ Heart Fail. 2017;10(1):e003255. https://doi.org/10.1161/CIRCHEARTFAILURE.116.003255.
Velazquez EJ, Lee KL, Jones RH, Al-Khalidi HR, Hill JA, Panza JA, et al. Coronary-artery bypass surgery in patients with ischemic cardiomyopathy. N Engl J Med. 2016;374(16):1511–20. https://doi.org/10.1056/NEJMoa1602001.
Article CAS PubMed PubMed Central Google Scholar
Saltiel J, Lespérance J, Bourassa MG, Castonguay Y, Campeau L, Grondin P. Reversibily of left ventricular dysfunction following aorto-coronary by-pass grafts. Am J Roentgenol Radium Ther Nucl Med. 1970;110(4):739–46. https://doi.org/10.2214/ajr.110.4.739.
Article CAS PubMed Google Scholar
Horn HR, Teichholz LE, Cohn PF, Herman MV, Gorlin R. Augmentation of left ventricular contraction pattern in coronary artery disease by an inotropic catecholamine. The epinephrine ventriculogram. Circulation. 1974;49(6):1063–71. https://doi.org/10.1161/01.cir.49.6.1063.
Article CAS PubMed Google Scholar
Rahimtoola SH. The hibernating myocardium. Am Heart J. 1989;117(1):211–21. https://doi.org/10.1016/0002-8703(89)90685-6.
Article CAS PubMed Google Scholar
Rahimtoola SH. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina. Circulation. 1985;72(6 Pt 2):V123–235.
Uebleis C, Hellweger S, Laubender RP, et al. The amount of dysfunctional but viable myocardium predicts long-term survival in patients with ischemic cardiomyopathy and left ventricular dysfunction. Int J Cardiovasc Imaging. 2013;29(7):1645–53. https://doi.org/10.1007/s10554-013-0254-2.
Allman KC, Shaw LJ, Hachamovitch R, Udelson JE. Myocardial viability testing and impact of revascularization on prognosis in patients with coronary artery disease and left ventricular dysfunction: a meta-analysis. J Am Coll Cardiol. 2002;39(7):1151–8. https://doi.org/10.1016/s0735-1097(02)01726-6.
Orlandini A, Castellana N, Pascual A, Botto F, Bahot MC, Chacon C, Diaz ML, Diaz R. Myocardial viability for decision-making concerning revascularization in patients with left ventricular dysfunction and coronary artery disease: a meta-analysis of non-randomized and randomized studies. Int J Cardiol. 2015;182:494–9. https://doi.org/10.1016/j.ijcard.2015.01.025.
Inaba Y, Chen JA, Bergmann SR. Quantity of viable myocardium required to improve survival with revascularization in patients with ischemic cardiomyopathy: a meta-analysis. J Nucl Cardiol. 2010;17(4):646–54. https://doi.org/10.1007/s12350-010-9226-2.
McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599–726. https://doi.org/10.1093/eurheartj/ehab368.
留言 (0)